Psilocybin

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

Psilocybin significantly reduced depression symptoms in patients with cancer, results from a phase 2 study published in Cancer showed.

The U.S. has issued patents covering several advances in psychedelic therapy, including the “world’s first” new forms of psilocybin and orally active DMT and 5-MeO-DMT, according to a press release from the manufacturer.

With potential FDA approvals on the horizon, the controversy surrounding psychedelics in clinical practice may soon reach a tipping point, according to experts.

A single dose of Cybin Inc.’s CYB003, an investigational deuterated psilocybin analog, resulted in statistically significant improvement in depression symptoms after 3 weeks compared with placebo, the company announced in a press release.

Mental health conditions affect one in eight people and one in seven adolescents worldwide, according to WHO.

A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental health disorders.

SAN DIEGO — Psilocybin has emerged as a potential treatment for depression and anxiety, including among patients with chronic rheumatic or autoimmune conditions, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

A single dose of psilocybin resulted in clinically and statistically significant reductions in depressive symptoms and functional disability compared with placebo in patients with major depressive disorder, according to a phase 2 study.

The prevalence of distress among women with late-stage gynecologic cancers calls for well-designed studies to assess the safety and efficacy of psychedelics for this patient population, according to authors of a published commentary.